Technical Analysis for MACK - Merrimack Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 3.95 -8.14% -0.35
MACK closed down 8.14 percent on Friday, November 15, 2019, on 4.74 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical MACK trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
New Downtrend Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Volume Surge Other 0.00%
Upper Bollinger Band Touch Strength 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -8.14%
Lower Bollinger Band Walk Weakness -8.14%
Inside Day Range Contraction -8.14%
Upper Bollinger Band Touch Strength -8.14%
Slingshot Bearish Bearish Swing Setup -7.06%

Older signals for MACK ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer in the United States. The company uses its Network Biology proprietary systems biology-based approach to biomedical research. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for various cancers; MM-121, a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in cancer, which is in multiple ongoing Phase I and Phase II clinical trials; and MM-111, a bispecific antibody designed to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell receptor, which is in multiple ongoing Phase I and Phase II clinical trials. The company's product candidates also include MM-302, a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 (HER2) receptor in Phase 1 clinical trial in patients with advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trial; and MM-141, a human tetravalent bispecific antibody designed to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3, which is in Phase 1 clinical trial. It has collaboration and license agreements with Sanofi; Dyax Corp.; PharmaEngine, Inc.; Adimab LLC; University of California; U.S. Public Health Service; and Selexis SA. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Medicine Biopharmaceutical Cancer Treatment Of Cancer Antibodies Cancers Chemotherapy Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Her2/Neu University Of California Erb B3 Mm 151
Is MACK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.5
52 Week Low 3.7
Average Volume 49,346
200-Day Moving Average 5.7482
50-Day Moving Average 4.5678
20-Day Moving Average 4.035
10-Day Moving Average 3.988
Average True Range 0.2153
ADX 31.5
+DI 20.5097
-DI 22.1654
Chandelier Exit (Long, 3 ATRs ) 3.7641
Chandelier Exit (Short, 3 ATRs ) 4.3659
Upper Bollinger Band 4.3001
Lower Bollinger Band 3.7699
Percent B (%b) 0.34
BandWidth 13.140025
MACD Line -0.1461
MACD Signal Line -0.2083
MACD Histogram 0.0622
Fundamentals Value
Market Cap 52.45 Million
Num Shares 13.3 Million
EPS 32.12
Price-to-Earnings (P/E) Ratio 0.12
Price-to-Sales 1.06
Price-to-Book 1.44
PEG Ratio 0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.52
Resistance 3 (R3) 4.58 4.46 4.43
Resistance 2 (R2) 4.46 4.31 4.43 4.39
Resistance 1 (R1) 4.20 4.22 4.14 4.14 4.36
Pivot Point 4.08 4.08 4.04 4.04 4.08
Support 1 (S1) 3.82 3.93 3.76 3.76 3.54
Support 2 (S2) 3.70 3.84 3.66 3.51
Support 3 (S3) 3.44 3.70 3.47
Support 4 (S4) 3.38